BEAM Alliance, the European AMR innovation hub gathering biotech companies

BEAM Alliance, The European AMR innovation hub

gathering Biotech companies.

BEAM Alliance, focus on patients first, voices the needs of biotech companies

BEAM Alliance, Focus on Patients first,

Voices the needs of Biotech companies.

How the EU Pharmaceutical Strategy could help prevent the next pandemic

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

read more >>

BEAM Alliance wants HERA  to effectively support R&D in antimicrobial resistance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

read more >>

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

​20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

read more >>

AMR: The life of innovative SMEs

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

read more >>

About us

Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance is a strong Network of approx. 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices including in vitro diagnostics.

BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.

Why Innovate In Anti-Microbial Resistance?

Antimicrobial Resistance has now gained the spotlight from governments worldwide as an urgent threat. Back in 2016 the Davos Declaration also clearly demonstrated the commitment of the pharmaceutical industry to combating the challenge of AMR with signatures by over 100 companies and organizations. The BEAM Alliance was a key influencer in this declaration and, since then, has multiplied actions in outlaying the challenges associated with combating AMR from an industry perspective.

Developing new solutions to combat AMR is hampered by market failure as the corresponding products have costly R&D with low return on investment. A new paradigm to incentivize and encourage new products in the space is urgently needed and accompanying policies must embrace the vision of all the key players in the AMR sphere, particularly SMEs. Indeed, SMEs are collectively developing a broad portfolio of preventive, diagnostic and therapeutic products but are struggling to survive owing to the significant lack of investment in the field.

The BEAM Alliance is advocating for SME-compatible policies that are flexible enough to incorporate the vast variety of tools needed to tackle AMR.

Get Involved, Join the BEAM Alliance!

Every new member makes the BEAM Alliance stronger. If you wish to join, you can apply here or contact us for any question!

Together with Full and International members, i.e. SMEs developing AMR products, we also welcome Associated members, whose contribution to the ecosystem is essential.
We aim at easing the collaboration between skilled professionals for the benefit of product development; our Associated members’ booklet is here to help you find the expertise to match your needs.

Board Members

 

BEAM Alliance in numbers


  • 68

    Members

  • 2

    Products in market

  • 84

    Products in preclinical research

  • 26

    Products in clinical development